Gynaecological cancer
DOI:
https://doi.org/10.3989/arbor.2015.773n3007Keywords:
cervix cáncer, ovarian cáncer, uterus cancerAbstract
Gynecological cancer is a major health problem in Europe, as taken together, ovarian cancer, cancer of the uterus and cervical cancer, represent the third cause of cancer in women in Europe, after breast cancer and colorectal cancer, and also the third cause of death from cancer after breast cancer and lung cancer. Improvement in these data entails the implementation of the prophylactic measures available. Especially in the case of cervical cancer, early diagnosis whenever it is possible, the administration of the best treatment by specialised multidisciplinary teams and knowledge of the molecular alterations associated with these diseases are required as a base for the development of personalised and effective treatments.
Downloads
References
Aalders, J., Abeler, V., Kolstad, P. y Onsrud, M. (1980). Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstetrics & Gynecolgy, 56, 4, pp. 419-427.
Armstrong, D., Bunden, B. y Wenel, L. (2006). Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. New England Journal of Medicine, 354, pp. 34-43. http://dx.doi.org/10.1056/NEJMoa052985
Ashworth, A. (2008). A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Journal of Clinical Oncology, 26, 22, pp. 3785-3790. http://dx.doi.org/10.1200/JCO.2008.16.0812
Bast, R. C., Jr., Hennessy, B. y Mills, G. B. (2009). The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer, 9, 6, pp. 415-428. http://dx.doi.org/10.1038/nrc2644
Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D. Dao, F., Dhir, R., DiSaia, P., Gabra, H. et al. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 7353, pp. 609-615. http://dx.doi.org/10.1038/nature10166
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H. et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, 365, 26, pp. 2473-2483. http://dx.doi.org/10.1056/NEJMoa1104390
Burke, W. M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A. B. et al. (2014a). Endometrial cancer: a review and current management strategies: part II. Gynecologic Oncology, 134, 2, pp. 393-402.
Burke, W. M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A. B. et al. (2014b). Endometrial cancer: a review and current management strategies: part I. Gynecologic Oncology, 134, 2, pp. 385-392.
Creutzberg, C. L., van Putten, W. L., Koper, P. C., Lybeert, M. L., Jobsen, J. J., Warlam-Rodenhuis, C. C. et al. (2000). Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet, 355, 9213, pp. 1404-1411. http://dx.doi.org/10.1016/s0140-6736(00)02139-5
du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I. y Pfisterer, J. (2009a). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer, 115, 6, pp. 1234-1244.
du Bois, A., Rochon, J., Pfisterer, J. y Hoskins, W. J. (2009b). Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecologic Oncology, 112, 2, pp. 422-436.
Gonzalez-Martin, A., Bover, I., Del Campo, J. M., Redondo, A. y Vidal, L. (2014). SEOM guideline in ovarian cancer 2014. Clinical and Translational Oncology, 16, 12, pp. 1067-1071. http://dx.doi.org/10.1007/s12094-014-1229-z
Hogberg, T., Signorelli, M., de Oliveira, C. F., Fossati, R., Lissoni, A. A., Sorbe, B. et al. (2010). Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. European Journal of Cancer, 46, 13, pp. 2422-2431. http://dx.doi.org/10.1016/j.ejca.2010.06.002
Katsumata, N., Yasuda, M., Isonishi, S., Michimae, H., Kimura, E., Aoki, D. et al. (2012). Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. ASCO Meeting Abstracts, 30, abstract 5003.
Keys, H. M., Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D. et al. (2004). A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology, 92, 3, pp. 744-751. http://dx.doi.org/10.1016/j.ygyno.2003.11.048
Kitchener, H., Swart, A. M., Qian, Q., Amos, C. y Parmar, M. K. (2009). Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet, 373, 9658, pp. 125-136.
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G. et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine, 366, 15, pp. 1382-1392. http://dx.doi.org/10.1056/NEJMoa1105535
McGraw, S. L. y Ferrante, J. M. (2014). Update on prevention and screening of cervical cancer. World Journal of Clinical Oncology, 5, 4, pp. 744-752. http://dx.doi.org/10.5306/wjco.v5.i4.744
Nout, R. A., Smit, V. T., Putter, H., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. et al. (2010). Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet, 375, 9717, pp. 816-823. http://dx.doi.org/10.1016/S0140-6736(09)62163-2
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine, 365, 26, pp. 2484-2496. http://dx.doi.org/10.1056/NEJMoa1103799
Shih, K. K., Yun, E., Gardner, G. J., Barakat, R. R., Chi, D. S. y Leitao, M. M., Jr. (2011). Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecologic Oncology, 122, 3, pp. 608-611. http://dx.doi.org/10.1016/j.ygyno.2011.05.020
Stuart, G. C., Kitchener, H., Bacon, M., duBois, A., Friedlander, M., Ledermann, J. et al. (2011). 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. International Journal of Gynecological Cancer, 21, 4, pp. 750-755. http://dx.doi.org/10.1097/IGC.0b013e31821b2568
Susumu, N., Sagae, S., Udagawa, Y., Niwa, K., Kuramoto, H., Satoh, S. et al. (2008). Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecologic Oncology, 108, 1, pp. 226-233. http://dx.doi.org/10.1016/j.ygyno.2007.09.029
Tewari, K. S. y Monk, B. J. (2014). New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy. Clinical Cancer Research, 20, 21, pp. 5349-5358. http://dx.doi.org/10.1158/1078-0432.CCR-14-1099
Tewari, K. S., Sill, M. W., Long, H. J., 3rd, Penson, R. T., Huang, H., Ramondetta, L. M. et al. (2014). Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine, 370, 8, pp. 734-743. http://dx.doi.org/10.1056/NEJMoa1309748
Wright, J. D., Barrena Medel, N. I., Sehouli, J., Fujiwara, K. y Herzog, T. J. (2012). Contemporary management of endometrial cancer. Lancet, 379, 9823, pp. 1352-1360. http://dx.doi.org/10.1016/S0140-6736(12)60442-5
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 Consejo Superior de Investigaciones Científicas (CSIC)
This work is licensed under a Creative Commons Attribution 4.0 International License.
© CSIC. Manuscripts published in both the printed and online versions of this Journal are the property of Consejo Superior de Investigaciones Científicas, and quoting this source is a requirement for any partial or full reproduction.
All contents of this electronic edition, except where otherwise noted, are distributed under a “Creative Commons Attribution 4.0 International” (CC BY 4.0) License. You may read the basic information and the legal text of the license. The indication of the CC BY 4.0 License must be expressly stated in this way when necessary.
Self-archiving in repositories, personal webpages or similar, of any version other than the published by the Editor, is not allowed.
